{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:57:03Z","timestamp":1776275823727,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1C1C1013177"],"award-info":[{"award-number":["NRF-2021R1C1C1013177"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01509-8","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T18:53:31Z","timestamp":1739818411000},"page":"243-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-7135","authenticated-orcid":false,"given":"Jae Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0014-9465","authenticated-orcid":false,"given":"Ja-Young","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8190-2229","authenticated-orcid":false,"given":"Jae-Hee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5593-7672","authenticated-orcid":false,"given":"Myeong Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"1509_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.ajog.2013.04.019","volume":"209","author":"BK Erickson","year":"2013","unstructured":"Erickson BK, Conner MG, Landen CN Jr (2013) The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 209:409\u2013414","journal-title":"Am J Obstet Gynecol"},{"key":"1509_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3322\/caac.20113","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK (2011) Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 61:183\u2013203","journal-title":"CA Cancer J Clin"},{"key":"1509_CR3","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.3390\/ijms24087585","volume":"24","author":"A Zon","year":"2023","unstructured":"Zon A, Bednarek I (2023) Cisplatin in ovarian Cancer treatment-known limitations in Therapy Force New solutions. Int J Mol Sci 24:7585","journal-title":"Int J Mol Sci"},{"key":"1509_CR4","first-page":"304","volume":"5","author":"M Ortiz","year":"2022","unstructured":"Ortiz M, Wabel E, Mitchell K, Horibata S (2022) Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist 5:304\u2013316","journal-title":"Cancer Drug Resist"},{"key":"1509_CR5","doi-asserted-by":"publisher","first-page":"102925","DOI":"10.1016\/j.bioorg.2019.102925","volume":"88","author":"S Ghosh","year":"2019","unstructured":"Ghosh S (2019) Cisplatin: the first metal based anticancer drug. Bioorg Chem 88:102925","journal-title":"Bioorg Chem"},{"key":"1509_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejphar.2017.05.063","volume":"811","author":"R Oun","year":"2017","unstructured":"Oun R, Rowan E (2017) Cisplatin induced arrhythmia; electrolyte imbalance or disturbance of the SA node? Eur J Pharmacol 811:125\u2013128","journal-title":"Eur J Pharmacol"},{"key":"1509_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","volume":"22","author":"VB Pai","year":"2000","unstructured":"Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 22:263\u2013302","journal-title":"Drug Saf"},{"key":"1509_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3390\/antiox8090347","volume":"8","author":"JJ Xing","year":"2019","unstructured":"Xing JJ, Hou JG, Liu Y et al (2019) Supplementation of Saponins from leaves of Panax quinquefolius mitigates cisplatin-evoked cardiotoxicity via inhibiting oxidative stress-Associated inflammation and apoptosis in mice. Antioxid (Basel) 8:347","journal-title":"Antioxid (Basel)"},{"key":"1509_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.phrs.2005.12.005","volume":"53","author":"AA Al-Majed","year":"2006","unstructured":"Al-Majed AA, Sayed-Ahmed MM, Al-Yahya AA, Aleisa AM, Al-Rejaie SS, Al-Shabanah OA (2006) Propionyl-L-carnitine prevents the progression of cisplatin-induced cardiomyopathy in a carnitine-depleted rat model. Pharmacol Res 53:278\u2013286","journal-title":"Pharmacol Res"},{"key":"1509_CR10","doi-asserted-by":"publisher","first-page":"101154","DOI":"10.1016\/j.esmoop.2023.101154","volume":"8","author":"A Palazzo","year":"2023","unstructured":"Palazzo A, Ciccarese C, Iacovelli R et al (2023) Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis. ESMO Open 8:101154","journal-title":"ESMO Open"},{"key":"1509_CR11","doi-asserted-by":"publisher","first-page":"175883592311731","DOI":"10.1177\/17588359231173183","volume":"15","author":"H Hockings","year":"2023","unstructured":"Hockings H, Miller RE (2023) The role of PARP inhibitor combination therapy in ovarian cancer. Ther Adv Med Oncol 15:17588359231173183","journal-title":"Ther Adv Med Oncol"},{"key":"1509_CR12","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V et al (2019) A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 30:1437\u20131447","journal-title":"Ann Oncol"},{"key":"1509_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s12012-018-9462-2","volume":"18","author":"RJ Henning","year":"2018","unstructured":"Henning RJ, Bourgeois M, Harbison RD (2018) Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors: mechanisms of Action and Role in Cardiovascular disorders. Cardiovasc Toxicol 18:493\u2013506","journal-title":"Cardiovasc Toxicol"},{"key":"1509_CR14","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1007\/s00018-006-6345-7","volume":"63","author":"C Fiorillo","year":"2006","unstructured":"Fiorillo C, Ponziani V, Giannini L et al (2006) Protective effects of the PARP-1 inhibitor PJ34 in hypoxic-reoxygenated cardiomyoblasts. Cell Mol Life Sci 63:3061\u20133071","journal-title":"Cell Mol Life Sci"},{"key":"1509_CR15","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1006\/jmcc.1997.0496","volume":"29","author":"E Gilad","year":"1997","unstructured":"Gilad E, Zingarelli B, Salzman AL, Szabo C (1997) Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts in vitro. J Mol Cell Cardiol 29:2585\u20132597","journal-title":"J Mol Cell Cardiol"},{"key":"1509_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11239-008-0230-1","volume":"27","author":"DA Morrow","year":"2009","unstructured":"Morrow DA, Brickman CM, Murphy SA et al (2009) A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J Thromb Thrombolysis 27:359\u2013364","journal-title":"J Thromb Thrombolysis"},{"key":"1509_CR17","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1124\/jpet.300.3.862","volume":"300","author":"P Pacher","year":"2002","unstructured":"Pacher P, Liaudet L, Bai P et al (2002) Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure. J Pharmacol Exp Ther 300:862\u2013867","journal-title":"J Pharmacol Exp Ther"},{"key":"1509_CR18","first-page":"369","volume":"17","author":"P Pacher","year":"2006","unstructured":"Pacher P, Liaudet L, Mabley JG, Cziraki A, Hasko G, Szabo C (2006) Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med 17:369\u2013375","journal-title":"Int J Mol Med"},{"key":"1509_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.bcp.2004.11.023","volume":"69","author":"O Szenczi","year":"2005","unstructured":"Szenczi O, Kemecsei P, Holthuijsen MF et al (2005) Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure. Biochem Pharmacol 69:725\u2013732","journal-title":"Biochem Pharmacol"},{"key":"1509_CR20","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","volume":"32","author":"JA Kim","year":"2017","unstructured":"Kim JA, Yoon S, Kim LY, Kim DS (2017) Towards actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for Health Research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci 32:718\u2013728","journal-title":"J Korean Med Sci"},{"key":"1509_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u2013383","journal-title":"J Chronic Dis"},{"key":"1509_CR22","doi-asserted-by":"publisher","first-page":"847012","DOI":"10.3389\/fcvm.2022.847012","volume":"9","author":"MB Morelli","year":"2022","unstructured":"Morelli MB, Bongiovanni C, Da Pra S et al (2022) Cardiotoxicity of Anticancer drugs: molecular mechanisms and strategies for Cardioprotection. Front Cardiovasc Med 9:847012","journal-title":"Front Cardiovasc Med"},{"key":"1509_CR23","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","volume":"131","author":"D Cardinale","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G et al (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981\u20131988","journal-title":"Circulation"},{"key":"1509_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnci\/djw323","volume":"109","author":"XI Yao","year":"2017","unstructured":"Yao XI, Wang X, Speicher PJ et al (2017) Reporting and guidelines in propensity score analysis: a systematic review of cancer and cancer surgical studies. J Natl Cancer Inst 109:1\u20139","journal-title":"J Natl Cancer Inst"},{"key":"1509_CR25","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1470-2045(20)30447-2","volume":"21","author":"V Dieras","year":"2020","unstructured":"Dieras V, Han HS, Kaufman B et al (2020) Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:1269\u20131282","journal-title":"Lancet Oncol"},{"key":"1509_CR26","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","volume":"18","author":"YJ Bang","year":"2017","unstructured":"Bang YJ, Xu RH, Chin K et al (2017) Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18:1637\u20131651","journal-title":"Lancet Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01509-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01509-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:39:32Z","timestamp":1746193172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01509-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1509"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01509-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study received an exemption approval from the Institutional Review Board (ewha-202305-0014-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}